HCV Liver Disease Progression and Treatment

Fibrosis Staging and Diagnostic Methods

The European Association for the Study of the Liver recommends using the METAVIR scoring system to classify HCV liver disease progression, which includes stages F0 (no fibrosis) to F4 (cirrhosis) 1, 2
Liver biopsy is considered the reference method for assessing inflammation grade and fibrosis stage, while non-invasive methods like transient elastography and serum biomarkers are also validated for fibrosis assessment 2, 3
The American Association for the Study of Liver Diseases suggests that combination approaches using both blood tests and elastography can improve accuracy and reduce the need for biopsy 3

The American Association for the Study of Liver Diseases recommends prioritizing treatment for patients with F3-F4 fibrosis (advanced fibrosis/cirrhosis) due to higher risk of complications 1, 2
Patients with decompensated cirrhosis (Child-Pugh B and C) require urgent treatment with interferon-free regimens 1
The European Association for the Study of the Liver suggests that patients with significant extrahepatic manifestations, such as symptomatic vasculitis or HCV immune complex-related nephropathy, should be treated regardless of fibrosis stage 1

The American Association for the Study of Liver Diseases recommends assessing SVR (sustained virologic response) 12 weeks after treatment completion to confirm cure 4
Patients with cirrhosis require continued surveillance for hepatocellular carcinoma (HCC) even after achieving SVR, as the risk of HCC is significantly reduced but not eliminated 4
Inadequate staging can lead to missing liver disease progression, and disease severity evaluation should be performed regardless of ALT levels 3
Overlooking drug interactions can lead to adverse events, and evaluating potential drug-drug interactions with all concurrent medications is crucial 4